Ambrx, Inc. is a biopharmaceutical company with a mission to deliver breakthrough protein therapeutics. Ambrx is based on a fundamental advance in protein biosynthesis that enables the company to genetically engineer proteins with new amino acid building blocks beyond the common twenty, enabling the biosynthesis of proteins with new physical, chemical and pharmacological properties. By combing the versatility of medicinal chemistry with modern biotechnology, Ambrx is transforming the field of protein-based medicines. Ambrx completed a $12.5 million Series A preferred stock financing from investors including 5AM Ventures and Tavistock Life Sciences. Ambrx is based in San Diego, California and is currently recruiting a world-class scientific and commercialization team.
Ambrx Address
10975 North Torrey Pines Road San Diego, CA United States